An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT06768671 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2026-05-06
Summary
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Conditions
Interventions
- DRUG
-
Sonelokimab
Open label
Sponsors & Collaborators
-
MoonLake Immunotherapeutics AG
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 12 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-30
- Primary Completion
- 2026-09-28
- Completion
- 2026-09-28
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031 ·Status: RECRUITING ·Phase: PHASE2
-
Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.
NCT04061395 ·Status: COMPLETED ·Phase: PHASE2
-
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
NCT01832896 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
NCT01750697 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
NCT03569371 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07213973 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
NCT04976192 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
NCT05774639 ·Status: COMPLETED ·Phase: PHASE3
-
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
NCT05819775 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228 ·Status: RECRUITING ·Phase: PHASE3
-
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
NCT04206605 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04901195 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases
NCT01884311 ·Status: COMPLETED ·Phase: PHASE3
-
Use of KC706 for the Treatment of Pemphigus Vulgaris
NCT00606749 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
NCT06751238 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT03628924 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
NCT07024563 ·Status: RECRUITING ·Phase: PHASE3